SavedAdd your journal

Journals / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 4

The plasma microRNA levels and their relationship with the general health and functional status in female patients with fibromyalgia syndrome

Didem Havva ÇELİKCAN
Ali BİÇER
Orhan GÜVENER
Ayşegül GÖRÜR
Lülüfer TAMER
Erbil AKASLAN
Pages
482–492
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A strong positive correlation was found between miR-142-3p and the subscale score of SF-36 mental symptom score in female patients with FMS (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to identify the plasma level of micro-ribonucleic acid (microRNA) expressions and the relationship between plasma microRNA levels with the general health and functional status in female patients with fibromyalgia syndrome (FMS).
📊
Key Findings & Data:Patients and methods: Thirty-five female patients (mean age: 42.0±11.8 years; range, 21 to 62 years) diagnosed as FMS and 35 sex-and age-matched healthy controls (mean age: 43.7±8.8 years; range, 21 to 56 years) were enrolled in the study.
💡
Conclusion & Impact:A strong positive correlation was found between miR-142-3p and the subscale score of SF-36 mental symptom score in female patients with FMS (p
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to identify the plasma level of micro-ribonucleic acid (microRNA) expressions and the relationship between plasma microRNA levels with the general health and functional status in female patients with fibromyalgia syndrome (FMS). Patients and methods: Thirty-five female patients (mean age: 42.0±11.8 years; range, 21 to 62 years) diagnosed as FMS and 35 sex-and age-matched healthy controls (mean age: 43.7±8.8 years; range, 21 to 56 years) were enrolled in the study. MicroRNA measurements of the participants in plasma were carried out by using the quantitative polymerase chain reaction (qPCR). A total of 11 plasma levels of microRNA expressions were examined in both groups. The general health and functional status of the patients and controls were assessed by the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 (SF-36) scale. Results: No significant difference was observed between the plasma levels of microRNA expressions in patients with FMS and healthy controls. The plasma level of miR-320a expression was found to be negatively correlated with the total FIQ score in female patients with FMS (p=0.05, r=-0.34). Negative correlations were also detected between the plasma level of miR-320a and miR-320b expressions and the subscale score of SF-36 physical function in female patients with FMS (p=0.01, r=-0.43 and p=0.01, r=-0.43, respectively). A strong positive correlation was found between miR-142-3p and the subscale score of SF-36 mental symptom score in female patients with FMS (p

🔖

Cite This Article

ÇELİKCAN, D. H., BİÇER, A., GÜVENER, O., GÖRÜR, A., TAMER, L., AKASLAN, E. (2022). The plasma microRNA levels and their relationship with the general health and functional status in female patients with fibromyalgia syndrome. Archives of Rheumatology, Cilt: 36 - Sayı: 4, 482–492. https://ajindex.com/articles/448000

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Häuser W, Ablin J, Fitzcharles MA, Littlejohn G, Luciano JV, Usui C, et al. Fibromyalgia. Nat Rev Dis Primers 2015;1:15022
  2. Araújo FM, DeSantana JM. Physical therapy modalities for treating fibromyalgia. F1000Res 2019;8:F1000 Faculty Rev-2030
  3. Bjersing JL, Bokarewa MI, Mannerkorpi K. Profile of circulating microRNAs in fibromyalgia and their relation to symptom severity: An exploratory study. Rheumatol Int 2015;35:635-42
  4. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. Nat Rev Rheumatol 2013;9:340-50
  5. Niederberger E, Kynast K, Lötsch J, Geisslinger G. MicroRNAs as new players in the pain game. Pain 2011;152:1455-8
  6. Kynast KL, Russe OQ, Geisslinger G, Niederberger E. Novel findings in pain processing pathways: implications for miRNAs as future therapeutic targets. Expert Rev Neurother 2013;13:515-25
  7. Shenouda SK, Alahari SK. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78
  8. Lutz BM, Bekker A, Tao YX. Noncoding RNAs: New players in chronic pain. Anesthesiology 2014;121:409-17
  9. Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 2010;6:391-8
  10. Li X, Kroin JS, Kc R, Gibson G, Chen D, Corbett GT, et al. Altered spinal microRNA-146a and the microRNA-183 cluster contribute to osteoarthritic pain in knee joints. J Bone Miner Res 2013;28:2512-22
  11. Orlova IA, Alexander GM, Qureshi RA, Sacan A, Graziano A, Barrett JE, et al. MicroRNA modulation in complex regional pain syndrome. J Transl Med 2011;9:195
  12. Bjersing JL, Lundborg C, Bokarewa MI, Mannerkorpi K. Profile of cerebrospinal microRNAs in fibromyalgia. PLoS One 2013;8:e78762
  13. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33
  14. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9-12
  15. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33(4 Suppl):AS264-79
  16. Ware JE Jr, Sherbourne CD. The MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
  17. Kocyigit H. Reliability and validity